Andrea Sabens Sells 341 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $61.24, for a total value of $20,882.84. Following the transaction, the chief accounting officer now directly owns 63,239 shares of the company’s stock, valued at approximately $3,872,756.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Andrea Sabens also recently made the following trade(s):

• On Tuesday, February 13th, Andrea Sabens sold 341 shares of Lantheus stock. The stock was sold at an average price of $55.31, for a total value of $18,860.71.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $62.33 on Friday. The firm’s 50-day moving average price is $60.66 and its 200-day moving average price is $62.99. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $100.85. The company has a market cap of $4.27 billion, a PE ratio of 13.43 and a beta of 0.53. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The company had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 5.72 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LNTH. B. Riley upped their price target on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday. JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Finally, Truist Financial restated a “buy” rating and issued a $82.00 price objective (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average target price of $104.71.

Hedge Funds Weigh In On Lantheus

A number of institutional investors and hedge funds have recently modified their holdings of the company. Tucker Asset Management LLC lifted its holdings in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 282 shares during the period. Principal Securities Inc. purchased a new position in shares of Lantheus in the fourth quarter worth approximately $28,000. First Horizon Advisors Inc. grew its position in Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 225 shares during the period. West Tower Group LLC increased its holdings in Lantheus by 534.1% during the fourth quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 438 shares during the last quarter. Finally, Parkside Financial Bank & Trust raised its position in Lantheus by 60.2% in the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 160 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.